Samuel G. Armato to Placebos
This is a "connection" page, showing publications Samuel G. Armato has written about Placebos.
Connection Strength
0.026
-
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15.
Score: 0.026